预期集团于2025年中期期间的纯利大幅减少，主要是由于(i)缺少于2024年中期期间因按折让价赎回公司 原订于2026年到期的优先票据而确认的溢利约人民币10.83亿元;及(ii)来自医疗产品分部的收益减少所 致。 巨星医疗控股(02393)发布公告，相比集团于截至2024年6月30日止6个月的未经审核综合纯利约人民币 10.93亿元，预期集团于截至2025年6月30日止6个月的未经审核综合纯利将大幅减少至不少于人民币 1000万元。 ...

Core Viewpoint - Yingmei Holdings (02028) experienced a significant decline of over 30% in its stock price, dropping 30.49% to HKD 0.155, with a trading volume of HKD 3.6113 million [1] Group 1: Stock Performance - The stock was temporarily suspended from trading yesterday and continued to decline after resuming trading this morning [1] - Prior to the decline, the stock had surged dramatically, with a cumulative increase of 346% over the previous two trading days [1] Group 2: Financial Outlook - Yingmei Holdings announced an expected loss of RMB 35 million to 40 million for the first half of 2025, compared to a loss of RMB 43.495 million in the same period last year [1] - The primary reasons for the anticipated losses include a decrease in printer demand, asset impairment provisions, and the lack of significant sales in medical products [1]

Core Viewpoint - Yingmei Holdings (02028) experienced a significant decline of over 30% in its stock price, attributed to a recent announcement of expected losses and a drop in printer demand [1] Company Summary - Yingmei Holdings' stock price fell by 30.49%, trading at HKD 0.155, with a trading volume of HKD 3.6113 million [1] - The company had previously seen a substantial increase in stock price, with a cumulative rise of 346% over the last two trading days [1] - The company announced an expected loss of RMB 35 million to 40 million for the first half of 2025, compared to a loss of RMB 43.495 million in the same period last year [1] - The primary reasons for the anticipated losses include a decline in printer demand, asset impairment provisions, and the lack of scale in medical product sales [1]

Group 1 - The core viewpoint of the article indicates that Yingmei Holdings (02028) is expecting a loss of RMB 35 million to 40 million in the first half of 2025, following a loss of RMB 43.495 million in the same period last year [1] - The primary reasons for the losses are attributed to a decline in printer demand, asset impairment provisions, and the lack of scale sales in medical products [1] - The company has applied for its shares to resume trading starting from 9:00 AM on August 13, 2025 [1]

格隆汇8月12日丨映美控股(02028.HK)公布，相比去年同期亏损人民币43.495百万元，集团预期于截至 2025年6月30日止六个月录得亏损人民币35百万元至人民币40百万元。 亏损的主要原因乃由于打印机需求下降和计提资产减值，以及医疗产品尚未形成规模销售导致。公司已 向联交所申请自2025年8月13日上午九时正起恢复股份买卖。 ...

Company Performance - Maravai LifeSciences Holdings, Inc. reported a quarterly loss of $0.08 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.06, marking an earnings surprise of -33.33% [1] - The company posted revenues of $47.4 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 2.23%, and a significant decline from year-ago revenues of $73.4 million [2] - Over the last four quarters, Maravai has not surpassed consensus EPS estimates and has topped consensus revenue estimates only once [2] Stock Performance - Maravai LifeSciences shares have declined approximately 59.6% since the beginning of the year, contrasting with the S&P 500's gain of 8.6% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.05 on revenues of $50.74 million, and for the current fiscal year, it is -$0.24 on revenues of $196.21 million [7] Industry Outlook - The Medical - Products industry, to which Maravai belongs, is currently ranked in the bottom 38% of over 250 Zacks industries, indicating potential challenges ahead [8] - The performance of Maravai's stock may be influenced by the overall outlook for the industry, as research shows that the top 50% of Zacks-ranked industries outperform the bottom 50% by more than 2 to 1 [8]

Myomo, Inc. (MYO) came out with a quarterly loss of $0.11 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.03 per share a year ago. These figures are adjusted for non-recurring items. Ahead of this earnings release, the estimate revisions trend for Myomo was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares ...

Company Performance - SurModics reported quarterly earnings of $0.06 per share, exceeding the Zacks Consensus Estimate of a loss of $0.21 per share, and improved from a loss of $0.27 per share a year ago, representing an earnings surprise of +128.57% [1] - The company posted revenues of $29.57 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 4.29%, although this is a decline from year-ago revenues of $30.34 million [2] - Over the last four quarters, SurModics has surpassed consensus EPS estimates three times and topped consensus revenue estimates two times [2] Stock Outlook - SurModics shares have declined approximately 11.6% since the beginning of the year, contrasting with the S&P 500's gain of 7.8% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.18 on revenues of $29.98 million, and for the current fiscal year, it is -$0.57 on revenues of $116.33 million [7] - The estimate revisions trend for SurModics was unfavorable prior to the earnings release, resulting in a Zacks Rank 5 (Strong Sell) for the stock, indicating expected underperformance in the near future [6] Industry Context - The Medical - Products industry, to which SurModics belongs, is currently ranked in the bottom 39% of over 250 Zacks industries, suggesting that the outlook for the industry can significantly impact stock performance [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Financial Performance - TerrAscend Corp. reported a quarterly loss of $0.03 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.02, marking an earnings surprise of -50.00% [1] - The company posted revenues of $65.01 million for the quarter ended June 2025, slightly surpassing the Zacks Consensus Estimate by 0.21%, but down from $77.52 million a year ago [2] - Over the last four quarters, TerrAscend has surpassed consensus EPS estimates only once and has topped consensus revenue estimates two times [2] Stock Performance - TerrAscend Corp. shares have declined approximately 24.5% since the beginning of the year, contrasting with the S&P 500's gain of 7.9% [3] - The current Zacks Rank for TerrAscend is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.02 on revenues of $74.6 million, and for the current fiscal year, it is -$0.10 on revenues of $293.57 million [7] - The trend of estimate revisions for TerrAscend was mixed ahead of the earnings release, which could change following the recent report [6] Industry Context - The Medical - Products industry, to which TerrAscend belongs, is currently ranked in the bottom 37% of over 250 Zacks industries, suggesting potential challenges for stock performance [8]

Core Viewpoint - VAREX IMAGING reported quarterly earnings of $0.18 per share, significantly exceeding the Zacks Consensus Estimate of $0.04 per share, marking an earnings surprise of +350.00% [1][2] Financial Performance - The company achieved revenues of $203 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 6.73%, although this represents a decline from year-ago revenues of $209.1 million [2] - Over the last four quarters, VAREX IMAGING has consistently surpassed consensus EPS estimates four times and topped consensus revenue estimates three times [2] Stock Performance - VAREX IMAGING shares have declined approximately 51.8% since the beginning of the year, contrasting with the S&P 500's gain of 7.9% [3] - The current Zacks Rank for VAREX IMAGING is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Earnings Outlook - The consensus EPS estimate for the upcoming quarter is $0.08 on revenues of $199.03 million, while the estimate for the current fiscal year is $0.42 on revenues of $801.93 million [7] - The trend of estimate revisions for VAREX IMAGING was mixed prior to the earnings release, which may change following the recent results [6] Industry Context - The Medical - Products industry, to which VAREX IMAGING belongs, is currently ranked in the bottom 37% of over 250 Zacks industries, suggesting potential challenges ahead [8]